Return to search results.
Complete title: An Open-Label, Phase 1, Dose-Escalation Study Evaluating the Safety and Tolerability of GDC-0853 in Patients with Relapsed or Refractory B-Cell Non-Hodgkins Lymphoma and Chronic Lymphocytic Leukemia
|Research Study Number||20132046|
|Principal Investigator||Stephen Smith|
Research Study Description
Eligibility Criteria (must meet the following to participate in this study)
Other eligibility criteria may apply.
Hematologic Malignancies; Leukemia; Lymphoma; Lymphoproliferative Disease
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.